Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Carcinoma, Ovarian Epithelial 1Brenner Tumor 1

Interventions

Specimen Handling 95Biopsy 79Magnetic Resonance Spectroscopy 74Paclitaxel 56Cyclophosphamide 53Cisplatin 53Radiotherapy 51Carboplatin 50Gemcitabine 43Bortezomib 38Irinotecan 37Taxes 32Fluorouracil 32Radiation 30veliparib 29Filgrastim 29Doxorubicin 29Vorinostat 27Oxaliplatin 27Leucovorin 27Ipilimumab 27alvocidib 26Cytarabine 26Temozolomide 25aldesleukin 24Rituximab 24fludarabine 23Etoposide 23Decitabine 23temsirolimus 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NIH × trioctyl phosphine oxide × Clear all
NCT00068484 2013-02-01

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00002913 2013-01-24

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡